When should serum testosterone levels be rechecked when administering intramuscular testosterone every two weeks?

When to Recheck Testosterone on Every-2-Week IM Dosing

Recheck serum testosterone levels 3 to 6 months after initiating intramuscular testosterone therapy, drawing the blood sample midway between injections (at approximately 1 week for every-2-week dosing). 1

Initial Monitoring Timeline

The Endocrine Society guidelines are explicit about the timing and methodology for testosterone monitoring with injectable testosterone enanthate or cypionate:

• First recheck: 3 to 6 months after treatment initiation 1
• Timing of blood draw: Midway between injections (approximately day 7 for every-2-week dosing) 1
• Target range: Mid-normal testosterone levels (approximately 400-700 ng/dL) 1

This midpoint timing is critical because injectable testosterone esters produce significant peak-trough variation. Research demonstrates that 200 mg every 2 weeks causes testosterone levels to peak 2-5 days post-injection (often reaching supraphysiologic levels) and decline to baseline or below by days 13-14 2, 3. Measuring at the trough (just before the next injection) may underestimate average exposure, while measuring at the peak overestimates it.

Dose Adjustment Criteria

Adjust the dose or frequency if the midpoint testosterone level is >700 ng/dL or <400 ng/dL 1. This is where clinical judgment becomes essential:

• If >700 ng/dL at midpoint: Consider reducing dose or switching to more frequent injections (weekly dosing with half the dose)
• If <400 ng/dL at midpoint: Consider increasing dose, though recognize this may worsen peak-trough fluctuations
• If symptomatic cycling occurs despite mid-normal levels: Consider weekly dosing (100 mg weekly instead of 200 mg every 2 weeks) to reduce fluctuation 4

Ongoing Monitoring Schedule

After the initial 3-6 month check:

• Annual testosterone monitoring if levels are stable and therapeutic 1
• Hematocrit monitoring: Baseline, 3-6 months, then annually 1
• PSA and digital rectal exam: For men ≥40 years with baseline PSA >0.6 ng/mL, check at 3-6 months, then per age-appropriate screening guidelines 1

Common Pitfalls to Avoid

Do not draw testosterone levels at random times in the dosing cycle. Without knowing when the last injection was given and when the blood was drawn, the result is uninterpretable 4. Always document:

• Testosterone ester type (enanthate vs cypionate)
• Dose and concentration
• Injection interval
• Date of last injection
• Date of blood draw

Do not assume every-2-week dosing is optimal for all patients. While convenient, this interval produces the widest peak-trough variation. Many patients experience early-cycle symptoms (acne, mood changes, fluid retention) from supraphysiologic peaks and late-cycle symptoms (fatigue, low libido) from subtherapeutic troughs 4, 2. Weekly dosing with half the dose often provides more stable symptom control without changing total weekly testosterone exposure.

Do not escalate the dose without first considering dose redistribution. If a patient reports late-cycle symptoms but has adequate midpoint levels, the issue is likely peak-trough variation rather than insufficient total dose 4. Switching to more frequent injections may resolve symptoms without increasing total weekly testosterone.

Safety Monitoring Context

The 3-6 month recheck serves dual purposes: efficacy assessment (symptom improvement, testosterone levels) and safety monitoring (hematocrit, PSA if indicated). Stop therapy if hematocrit exceeds 54%, evaluate for hypoxia and sleep apnea, and reinitiate at a reduced dose only after hematocrit normalizes 1. This is a hard safety threshold, not a suggestion.